GSK, MMV positive on single-dose tafenoquine reducing malaria risk

NaijaAgroNet:

The GSK and Medicines for Malaria Venture (MMV) has announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax (P.vivax) malaria, reports NaijaAgroNet.

The headline results, presented today at the International Conference on Plasmodium vivax Research (ICPVR) in Manaus, Brazil, show that a single-dose of 300mg tafenoquine, when given with a 3-day blood-stage chloroquine treatment, reduced the risk of relapse in patients with P.vivax malaria significantly more than placebo when given with chloroquine.

P. vivax is one of several species of Plasmodium parasite known to cause malaria. After an infected mosquito bite, the parasite has the ability to lie dormant in the liver and periodically reactivate causing relapses of P. vivax malaria. These relapses can occur weeks or even years after the initial infection. The disease is estimated to cause around 8.5 million clinical infections every year. Each of these infections keeps a child or adult from school or work for at least 3 days.² Studies have shown that beyond lost time, malaria can also have adverse effects on cognitive ability.

Since 2008, GSK and MMV have been working together to develop single-dose tafenoquine as an alternative to the existing standard of care, primaquine, which must be taken for 14 days for patients with the relapsing form of malaria. The two phase III randomised, double-blind studies, “DETECTIVE” and “GATHER”, were conducted in malaria-endemic countries covering South America, Asia, and Africa.

... Linking agrobiz, sustainable environs, people & technology

GSK dangles N1.1trn on researchers on non-communicable diseases

NaijaAgroNet:

GSK has launched the first call for proposals of its Africa NCD Open Lab, to support much-needed scientific research into non-communicable diseases (NCDs) in Africa with the sum of £4 million, about N1.1 trillion reports NaijaAgroNet.

Sources at GSK, confirmed to NaijaAgroNet that estimated £4m is now available for grabs as first funding round, to support successful proposals from researchers in Côte d’Ivoire, Cameroon, Ghana, The Gambia, Nigeria, Kenya, Uganda and Malawi. 

NaijaAgroNet notes that the Africa NCD Open Lab was established by GSK earlier this year, with a commitment of £25m funding over five years, as part of a series of strategic investments in sub-Saharan Africa. 

In this region, and across developing countries, NaijaAgroNet reports that non-communicable diseases, such as cancer and diabetes, are becoming more prevalent, and we need to learn more about how – and why – these diseases manifest differently in this setting. 

NaijaAgroNet also reports that Africa NCD Open Lab aims to address this through the creation of an innovative research network that will see GSK scientists collaborate with researchers across Africa on high quality epidemiological, genetic and interventional research, from its hub at GSK’s Stevenage R&D facility in the United Kingdom (UK).

This, experts affirmed to NaijaAgroNet will specifically inform interventions for the prevention and treatment of five priority diseases - cancer, cardiovascular disease, diabetes, chronic kidney disease and chronic respiratory disease – while helping build local expertise and creating a new generation of African NCD professionals.

Also, NaijaAgroNet reports that this builds on the success of GSK’s Open Lab in Tres Cantos, Spain which provides independent researchers access to GSK facilities, resources and knowledge to help them advance their own research projects into diseases of the developing world such as malaria, tuberculosis and leishmaniasis. Since the Tres Cantos Open Lab was established, 15 projects from world class institutions have been completed, progressing much needed research into diseases of the developing world.  

Further, NaijaAgroNet  gathered, an independent external advisory group, comprising clinical and scientific experts in the field of NCDs, will review applications to the NCD Open Lab, with recommendations for funding based on scientific merit. The group will consist of a majority African membership to ensure that only locally-relevant research is funded.

In addition, NaijaAgroNet reports that a second call for proposals in South Africa has been planned for early in 2015 which will be launched in collaboration with the Medical Research Councils of South Africa and the UK, with a combined £5m funding.

Dr. Mike Strange, Interim Head of the Africa NCD Open Lab, said: “We believe the highly collaborative research network we’re creating through the Africa NCD Open Lab has the potential to dramatically improve understanding of NCDs in Africa – and could ultimately, accelerate the development of new, better medicines to treat these.

“The launch of our first call for proposals is an important milestone for this initiative, and we encourage researchers working in the field of NCDs who are based in the eight eligible countries to consider applying for the funding and expert support available to them through this,” he said.

 

... Linking agrobiz, sustainable environs, people & technology